The abstract is read at the publisher; the summary is JClub's.
Primary and first-booster mRNA COVID-19 vaccination during pregnancy is linked to lower COVID-19-related hospitalisation risk, with VE of 55.6% for primary vaccination.
- Why it matters: Real-world effectiveness of COVID-19 vaccination during pregnancy is still limited, especially across multiple European health systems and for infection versus severe outcomes.
- What they did: Using health data from the UK, Sweden, Spain, and Norway, the study emulated two target trials with weekly matching of vaccinated pregnant women to comparable unexposed women, totaling 62,061 and 41,096 participants.
- The result: Meta-analysis across databases estimated VE of 26.2% (95% CI 16.2–35.1) against infection and 55.6% (95% CI 44.1–64.8) against hospitalisation for primary vaccination; for boosters, VE was 33.6% (95% CI 1.6–56.6) against infection and 34.1% (95% CI 0.6–56.4) against hospitalisation, while ICU admission was too rare to analyze.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.